Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen Provides Update On Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma

[PR Newswire] – THOUSAND OAKS, Calif., April 4, 2014 /PRNewswire/ — Amgen (AMGN) today announced top-line results from the primary overall survival (OS) analysis of a Phase 3 trial in melanoma, which evaluated . . . → Read More: Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen Provides Update On Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma Similar Articles: Amgen Inc (NASDAQ:AMGN) – Amgen To Webcast Investor Meeting At Upcoming American College of Cardiology’s 63rd Annual Scientific Session Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen’s Talimogene Laherparepvec Reduced Size Of Melanoma Tumors In New Phase 3 Retrospective Analysis Merck & Co. Inc. (NYSE:MRK) – 8:31 am Merck initiates rolling submission of U.S. Biologics License Application for MK-3475, an investigational Anti-PD-1 Immunotherapy, in patients with advanced melanoma; expects to complete application in 1H14